Posted by Michael Wonder on 15 Jul 2016
Revlimid (lenalidomide) approved by the European Commission for the treatment of relapsed/refractory patients with Mantle cell lymphoma
15 July 2016 - Approved indication for Relvlimid (lenalidomide) offers a new option for European patients with relapsed/refractory mantle cell lymphoma, one of the poorest prognoses among all lymphomas.
Celgene today announced that the European Commission has approved Revlimid (lenalidomide) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
MCL is a rare sub-type of aggressive non-Hodgkin’s lymphoma (NHL), which starts in the lymph nodes but can move to other organs, causing tumours known as lymphomas. Between 3 and 6 percent of NHL patients have MCL. MCL has the poorest long-term survival of all B-cell lymphoma subtypes, with fewer than 50 percent of patients surviving at 5 years. In Europe there were 93,433 new cases of non-Hodgkin lymphoma, and 37,900 deaths in 2012. MCL has a median age of onset of 70 years and affects men more often than women.
